$PRPH
ProPhase Labs, Inc. Stock $prph

$prph Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000086827823000008 Filed on May 12, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$13.22M	$19.30M	$47.53M
YoY Change	-54.58%	-59.39%	211.27%
Cost Of Revenue	$6.769M	$8.783M	$18.85M
YoY Change	-34.74%	-53.42%	197.38%
Gross Profit	$6.448M	$10.52M	$28.68M
YoY Change	-65.56%	-63.32%	221.13%
Gross Profit Margin	48.79%	54.5%	60.33%
Selling, General & Admin	$9.937M	$8.298M	$7.824M
YoY Change	57.58%	6.06%	106.98%
% of Gross Profit	154.11%	78.88%	27.28%
Research & Development	$572.0K	$144.0K	$35.00K
YoY Change	1942.86%	311.43%	-70.83%
% of Gross Profit	8.87%	1.37%	0.12%
Depreciation & Amortization	$1.347M	$1.292M	$1.249M
YoY Change	121.91%	3.44%	131.3%
% of Gross Profit	20.89%	12.28%	4.36%
Operating Expenses	$11.11M	$9.645M	$12.53M
YoY Change	36.55%	-23.03%	62.53%
Operating Profit	-$4.658M	$875.0K	$16.15M
YoY Change	-144.0%	-94.58%	1223.44%
Interest Expense	$291.0K	$215.0K	-$236.0K
YoY Change	44.78%	-191.1%	47.5%
% of Operating Profit		24.57%	-1.46%
Other Income/Expense, Net	$8.000K	-$107.0K	-$76.00K
YoY Change		40.79%
Pretax Income	-$4.914M	$564.0K	$15.91M
YoY Change	-147.2%	-96.46%	1400.94%
Income Tax	-$1.474M	$14.00K	$3.416M
% Of Pretax Income		2.48%	21.47%
Net Earnings	-$3.440M	$550.0K	$12.49M
YoY Change	-146.2%	-95.6%	1078.68%
Net Earnings / Revenue	-26.03%	2.85%	26.29%
Basic Earnings Per Share	-$0.20	$0.03	$0.81
Diluted Earnings Per Share	-$0.20	$0.03	$666.7K
COMMON SHARES
Basic Shares Outstanding	17.18M shares	17.18M shares	15.49K shares
Diluted Shares Outstanding	16.85K shares	18.06K shares	18.74K shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.104M	$15.56M	$29.35M
YoY Change	-66.89%	-46.99%	-19.06%
Cash & Equivalents	$3.824M	$9.613M	$25.81M
Short-Term Investments	$5.280M	$5.946M	$3.543M
Other Short-Term Assets	$3.667M	$3.573M	$1.831M
YoY Change	129.47%	95.14%	195.32%
Inventory	$3.623M	$4.311M	$4.680M
Prepaid Expenses
Receivables	$38.57M	$37.84M	$36.69M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$54.97M	$61.28M	$72.56M
YoY Change	-21.78%	-15.54%	7.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.831M	$8.891M	$10.76M
YoY Change	41.25%	-17.36%	-8.2%
Goodwill	$5.231M	$5.231M
YoY Change	-8.37%
Intangibles	$13.77M	$14.52M
YoY Change	45.95%
Long-Term Investments
YoY Change
Other Assets	$1.163M	$1.163M	$499.0K
YoY Change	-9.28%	133.07%	-88.79%
Total Long-Term Assets	$36.09M	$34.10M	$27.11M
YoY Change	30.43%	25.77%	49.04%
TOTAL ASSETS
Total Short-Term Assets	$54.97M	$61.28M	$72.56M
Total Long-Term Assets	$36.09M	$34.10M	$27.11M
Total Assets	$91.06M	$95.37M	$99.67M
YoY Change	-7.03%	-4.31%	16.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.786M	$4.866M	$8.204M
YoY Change	7.67%	-40.69%	5.45%
Accrued Expenses	$1.527M	$802.0K	$3.511M
YoY Change	575.66%	-77.16%	-28.78%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$364.0K
YoY Change
Total Short-Term Liabilities	$13.68M	$18.47M	$19.77M
YoY Change	-18.22%	-6.59%	8.09%
LONG-TERM LIABILITIES
Long-Term Debt	$3.490M	$2.400M	$8.015M
YoY Change	-56.36%	-70.06%	-19.77%
Other Long-Term Liabilities	$14.64M	$14.57M	$4.992M
YoY Change	188.74%	191.79%	10.93%
Total Long-Term Liabilities	$18.13M	$16.97M	$13.01M
YoY Change	38.72%	30.44%	-10.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.68M	$18.47M	$19.77M
Total Long-Term Liabilities	$18.13M	$16.97M	$13.01M
Total Liabilities	$31.80M	$35.43M	$33.22M
YoY Change	6.75%	6.66%	1.34%
SHAREHOLDERS EQUITY
Retained Earnings	$8.863M	$12.30M
YoY Change	-33.01%
Common Stock	$17.00K	$17.00K
YoY Change	6.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$59.26M	$59.94M	$66.45M
YoY Change
Total Liabilities & Shareholders Equity	$91.06M	$95.37M	$99.67M
YoY Change	-7.03%	-4.31%	16.65%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$3.440M	$550.0K	$12.49M
YoY Change	-146.2%	-95.6%	1078.68%
Depreciation, Depletion And Amortization	$1.347M	$1.292M	$1.249M
YoY Change	121.91%	3.44%	131.3%
Cash From Operating Activities	-$6.957M	$476.0K	$20.29M
YoY Change	-244.31%	-97.65%	-357.12%
INVESTING ACTIVITIES
Capital Expenditures	-$2.244M	$3.421M	-$1.095M
YoY Change	232.94%	-412.42%	-72.14%
Acquisitions		$2.904M	$0.00
YoY Change
Other Investing Activities	-$1.029M	$1.769M	$5.179M
YoY Change	-653.23%	-65.84%	-277.97%
Cash From Investing Activities	$1.215M	-$1.652M	$4.084M
YoY Change	-348.98%	-140.45%	-159.8%
FINANCING ACTIVITIES
Cash Dividend Paid		$0.00	$4.646M
YoY Change		-100.0%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-47.00K	$1.680M	-7.222M
YoY Change	-99.24%	-123.26%	-117.77%
NET CHANGE
Cash From Operating Activities	-6.957M	$476.0K	20.29M
Cash From Investing Activities	1.215M	-$1.652M	4.084M
Cash From Financing Activities	-47.00K	$1.680M	-7.222M
Net Change In Cash	-5.789M	$504.0K	17.15M
YoY Change	213.26%	-97.06%	-33.84%
FREE CASH FLOW
Cash From Operating Activities	-$6.957M	$476.0K	$20.29M
Capital Expenditures	-$2.244M	$3.421M	-$1.095M
Free Cash Flow	-$4.713M	-$2.945M	$21.38M
YoY Change	-185.77%	-113.77%	-639.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000868278
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-21617
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	ProPhase Labs, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	23-2577138
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	711 Stewart Ave
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	5946000	usd
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Garden City
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	11530
CY2023Q1	dei	City Area Code CityAreaCode	(215)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	345-0919
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0005
CY2023Q1	dei	Trading Symbol TradingSymbol	PRPH
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17182841	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9613000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9109000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	8328000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	37836000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	37054000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	4311000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3976000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3573000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2366000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	61279000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	60833000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8891000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7288000	usd
CY2023Q1	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	121000	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	121000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3974000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4059000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	14524000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8475000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	5231000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	5709000	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	191000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	0	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1163000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1163000	usd
CY2023Q1	us-gaap	Assets Assets	95374000	usd
CY2022Q4	us-gaap	Assets Assets	87648000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4866000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5905000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	353000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1009000	usd
CY2023Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	151000	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	99000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	298000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	301000	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2841000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2499000	usd
CY2023Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	3849000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	4190000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6109000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2072000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	18467000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16075000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1160000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1059000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	224000	usd
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	7224000	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2023Q1	us-gaap	Unsecured Long Term Debt UnsecuredLongTermDebt	2400000	usd
CY2022Q4	us-gaap	Unsecured Long Term Debt UnsecuredLongTermDebt	2400000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4182000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4259000	usd
CY2023Q1	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	2000000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	0	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	16966000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7942000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	35433000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	24017000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0005
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0005
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	109138000	usd
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0005
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0005
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16851041	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16210776	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	17000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	16000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	111482000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	12303000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	11753000	usd
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	18934955	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	18126970	shares
CY2023Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	63953000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	58033000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	92000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	757000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	59941000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	63631000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	95374000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	87648000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19303000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47531000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8783000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	18854000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	10520000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	28677000	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	1203000	usd
CY2022Q1	us-gaap	Professional Fees ProfessionalFees	4672000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8298000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7824000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	144000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	9645000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	12531000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	875000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	16146000	usd
CY2023Q1	us-gaap	Interest Income Other InterestIncomeOther	11000	usd
CY2022Q1	us-gaap	Interest Income Other InterestIncomeOther	73000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	215000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	233000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	600000	usd
CY2022Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	4646000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-107000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-76000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	564000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	15910000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3416000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	550000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	12494000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	550000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	12494000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-665000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	37000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-115000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	12531000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.81
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.68
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16748	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15486	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18061	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18740	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	63631000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1000000	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	541000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-665000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	398000	usd
CY2023Q1	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	5379000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	947000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	550000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	59941000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	58628000	usd
CY2022Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1150000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	37000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	482000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	12494000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	66445000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	550000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	12494000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	-107000	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	-179000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1292000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1249000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	20000	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	85000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	83000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	0	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	23000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	947000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	482000	usd
CY2023Q1	prph	Change In Fair Value Of Investment Securities ChangeInFairValueOfInvestmentSecurities	0	usd
CY2022Q1	prph	Change In Fair Value Of Investment Securities ChangeInFairValueOfInvestmentSecurities	-76000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-147000	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-924000	usd
CY2023Q1	prph	Inventory Valuation Reserve InventoryValuationReserve	0	usd
CY2022Q1	prph	Inventory Valuation Reserve InventoryValuationReserve	25000	usd
CY2023Q1	prph	Noncash Interest Income On Secured Promissory Note Receivable NoncashInterestIncomeOnSecuredPromissoryNoteReceivable	-230000	usd
CY2022Q1	prph	Noncash Interest Income On Secured Promissory Note Receivable NoncashInterestIncomeOnSecuredPromissoryNoteReceivable	0	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	864000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1938000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	335000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	105000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2107000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	126000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	96000	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-360000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2661000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1178000	usd
CY2023Q1	prph	Increase Decrease In Accrued Diagnostic Services IncreaseDecreaseInAccruedDiagnosticServices	-656000	usd
CY2022Q1	prph	Increase Decrease In Accrued Diagnostic Services IncreaseDecreaseInAccruedDiagnosticServices	-878000	usd
CY2023Q1	prph	Increase Decrease In Accrued Advertising And Other Allowances IncreaseDecreaseInAccruedAdvertisingAndOtherAllowances	52000	usd
CY2022Q1	prph	Increase Decrease In Accrued Advertising And Other Allowances IncreaseDecreaseInAccruedAdvertisingAndOtherAllowances	0	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	443000	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	165000	usd
CY2023Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	0	usd
CY2022Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	443000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-80000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-73000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-341000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	2973000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	4037000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	770000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	476000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	20287000	usd
CY2023Q1	us-gaap	Escrow Deposits Related To Property Sales EscrowDepositsRelatedToPropertySales	478000	usd
CY2022Q1	us-gaap	Escrow Deposits Related To Property Sales EscrowDepositsRelatedToPropertySales	0	usd
CY2023Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	2904000	usd
CY2022Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	206000	usd
CY2023Q1	prph	Proceeds From Maturities Of Marketable Securities ProceedsFromMaturitiesOfMarketableSecurities	1291000	usd
CY2022Q1	prph	Proceeds From Maturities Of Marketable Securities ProceedsFromMaturitiesOfMarketableSecurities	5300000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Other Property Plant And Equipment ProceedsFromSaleOfOtherPropertyPlantAndEquipment	0	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Other Property Plant And Equipment ProceedsFromSaleOfOtherPropertyPlantAndEquipment	85000	usd
CY2023Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	517000	usd
CY2022Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1095000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1652000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4084000	usd
CY2023Q1	prph	Proceeds From Issuance Of Common Stock And Warrants From Private Offering ProceedsFromIssuanceOfCommonStockAndWarrantsFromPrivateOffering	7600000	usd
CY2022Q1	prph	Proceeds From Issuance Of Common Stock And Warrants From Private Offering ProceedsFromIssuanceOfCommonStockAndWarrantsFromPrivateOffering	0	usd
CY2023Q1	prph	Repurchase Of Common Stock For Payment Of Statutory Taxes Due On Cashless Exercise Of Stock Option RepurchaseOfCommonStockForPaymentOfStatutoryTaxesDueOnCashlessExerciseOfStockOption	5379000	usd
CY2022Q1	prph	Repurchase Of Common Stock For Payment Of Statutory Taxes Due On Cashless Exercise Of Stock Option RepurchaseOfCommonStockForPaymentOfStatutoryTaxesDueOnCashlessExerciseOfStockOption	0	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	541000	usd
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1150000	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
CY2022Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1426000	usd
CY2023Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	0	usd
CY2022Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	4646000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1680000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7222000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	504000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	17149000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9109000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8658000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9613000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	25807000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-1500000	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	203000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	241000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1623000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2023Q1	prph	Issuance Of Common Shares Related To Business Acquisition IssuanceOfCommonSharesRelatedToBusinessAcquisition	1000000	usd
CY2022Q1	prph	Issuance Of Common Shares Related To Business Acquisition IssuanceOfCommonSharesRelatedToBusinessAcquisition	0	usd
CY2023Q1	prph	Issuance Of Common Shares For Debt Conversion IssuanceOfCommonSharesForDebtConversion	0	usd
CY2022Q1	prph	Issuance Of Common Shares For Debt Conversion IssuanceOfCommonSharesForDebtConversion	-600000	usd
CY2023Q1	prph	Unrealized Loss Investments In Marketable Debt Securities UnrealizedLossInvestmentsInMarketableDebtSecurities	0	usd
CY2022Q1	prph	Unrealized Loss Investments In Marketable Debt Securities UnrealizedLossInvestmentsInMarketableDebtSecurities	37000	usd
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2022Q3	prph	Number Of Inhibitors NumberOfInhibitors	2	inhibitor
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include revenue recognition and the impact of the variable consideration of diagnostic test reimbursement rates, the provision for uncollectible receivables and billing errors, allowances, slow moving and/or dated inventory and associated provisions, the potential impairment of long-lived assets, stock based compensation valuations, income tax asset valuations and assumptions related to accrued advertising.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the condensed consolidated financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.</span></div>
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	2000000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	2000000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	2000000	usd
CY2023Q1	us-gaap	Marketable Securities MarketableSecurities	5946000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	8328000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P7Y
CY2023Q1	prph	Asset Acquisition Transaction Costs AssetAcquisitionTransactionCosts	200000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2251000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	500000	usd
CY2022Q4	prph	Asset Acquisition Consideration Transferred Liability Payoff AssetAcquisitionConsiderationTransferredLiabilityPayoff	1600000	usd
CY2022Q4	prph	Asset Acquisition Consideration Transferred Promissory Note Payoff AssetAcquisitionConsiderationTransferredPromissoryNotePayoff	400000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0005
CY2022Q4	prph	Asset Acquisition Shares Issued And Issuable Value Per Share AssetAcquisitionSharesIssuedAndIssuableValuePerShare	10.00
CY2022Q4	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	4600000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	500000	usd
CY2022Q4	prph	Asset Acquisition Consideration Transferred Promissory Note Payoff AssetAcquisitionConsiderationTransferredPromissoryNotePayoff	400000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	2000000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19100000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	12297000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4576000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3822000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14524000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8475000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	754000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	709000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2191000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2583000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2583000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1731000	usd
CY2023Q1	prph	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	3185000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14524000	usd
CY2022Q1	us-gaap	Cash Cash	1440548	usd
CY2022Q1	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	1400000	usd
CY2022Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	40548	usd
CY2022Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	5.75
CY2022Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1150000	usd
CY2022Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	2590548	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0005
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0005
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.30
CY2022Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	4600000	usd
CY2023Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	6000000	usd
CY2023Q1	us-gaap	Stock Repurchase Program Period In Force1 StockRepurchaseProgramPeriodInForce1	P6M
CY2023Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	6000000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	205000	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	900000	usd
CY2023Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	7.62
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	744369	shares
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5400000	usd
CY2023Q1	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	603881	shares
CY2023Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	10.00
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P5Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	300000	usd
CY2023Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P1Y
CY2023Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	900000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	500000	usd
CY2023Q1	prph	Share Based Payment Arrangement Expense Remaining ShareBasedPaymentArrangementExpenseRemaining	4700000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y10M24D
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0169
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.1013
CY2021Q2	prph	Manufacturing Agreement Renewal Options ManufacturingAgreementRenewalOptions	4	periods
CY2021Q2	prph	Manufacturing Agreement Renewal Period ManufacturingAgreementRenewalPeriod	P1Y
CY2021Q2	prph	Agreement Term AgreementTerm	P90D
CY2022Q3	prph	License Agreement Term LicenseAgreementTerm	P10D
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4500000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4600000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4000000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4100000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	204000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	204000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	204000	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	204000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	204000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	204000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	659000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	747000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	768000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	783000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	804000	usd
CY2023Q1	prph	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	3071000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6832000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2352000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4480000	usd
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19303000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47531000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8783000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	18854000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1237000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1176000	usd
CY2023Q1	prph	Operating And Other Expenses OperatingAndOtherExpenses	8612000	usd
CY2022Q1	prph	Operating And Other Expenses OperatingAndOtherExpenses	11591000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	564000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	15910000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3416000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	550000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	12494000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	550000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	12494000	usd
CY2023Q1	us-gaap	Assets Assets	95374000	usd
CY2022Q4	us-gaap	Assets Assets	87648000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	550000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	12494000	usd
CY2023Q1	prph	Interest On Unsecured Convertible Promissory Note InterestOnUnsecuredConvertiblePromissoryNote	60000	usd
CY2022Q1	prph	Interest On Unsecured Convertible Promissory Note InterestOnUnsecuredConvertiblePromissoryNote	232000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	610000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	12726000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16748	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15486	shares
CY2023Q1	prph	Incremental Common Shares Attributable To Call Options IncrementalCommonSharesAttributableToCallOptions	22	shares
CY2022Q1	prph	Incremental Common Shares Attributable To Call Options IncrementalCommonSharesAttributableToCallOptions	2232	shares
CY2023Q1	prph	Incremental Common Shares Attributable To Warrants IncrementalCommonSharesAttributableToWarrants	1051	shares
CY2022Q1	prph	Incremental Common Shares Attributable To Warrants IncrementalCommonSharesAttributableToWarrants	222	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	240	shares
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	800	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18061	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18740	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1451000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1265000	shares

Files In Submission

Name	View Source	Status
0000868278-23-000008-index-headers.html	Edgar Link	pending
0000868278-23-000008-index.html	Edgar Link	pending
0000868278-23-000008.txt	Edgar Link	pending
0000868278-23-000008-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
prph-20230331.htm	Edgar Link	pending
prph-20230331.xsd	Edgar Link	pending
prph-20230331xexx311.htm	Edgar Link	pending
prph-20230331xexx312.htm	Edgar Link	pending
prph-20230331xexx321.htm	Edgar Link	pending
prph-20230331xexx322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
prph-20230331_def.xml	Edgar Link	unprocessable
prph-20230331_cal.xml	Edgar Link	unprocessable
prph-20230331_lab.xml	Edgar Link	unprocessable
prph-20230331_pre.xml	Edgar Link	unprocessable
prph-20230331_htm.xml	Edgar Link	completed
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRPH
ProPhase Labs, Inc. Stock $prph

2023 Q2 Form 10-Q Financial Statement

#000086827823000008 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRPH ProPhase Labs, Inc. Stock $prph

2023 Q2 Form 10-Q Financial Statement

#000086827823000008 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRPH
ProPhase Labs, Inc. Stock $prph